Pulsenmore is an early-stage Israeli medical device company that makes portable, home-use ultrasound devices for pregnant women and patients undergoing fertility treatment. Its flagship product, the Pulsenmore ES, is a hand-sized device that plugs into a smartphone and lets pregnant women scan themselves at home without medical training. Scans are transmitted to the cloud for clinician review, either in real time via video call or asynchronously. The Pulsenmore FC is a similar device for women undergoing IVF, enabling self-scanning of ovarian follicles and endometrial tissue to reduce clinic visits during treatment cycles. Pulsenmore also has a pipeline product, the Pulsenmore MC, for lung fluid monitoring in patients with heart or kidney disease. Pulsenmore sells primarily to HMOs and hospitals, which distribute devices to patients. In Israel, Clalit — the country's largest HMO — accounts for the vast majority of revenue. The current model is largely hardware-based, with devices sold on a per-unit basis under multi-year agreements. For the U.S. market, Pulsenmore is developing a hybrid model, targeting roughly $1,000 per pregnancy for the device and aiming for a meaningful share of revenue from recurring SaaS fees for the clinician dashboard. The Pulsenmore ES received FDA clearance in October 2025, and the company's near-term growth is centered on a U.S. commercial launch in 2026, alongside expansion in Europe and Australia and the rollout of the Pulsenmore FC in Israel.